<DOC>
	<DOCNO>NCT01076972</DOCNO>
	<brief_summary>This non-interventional , post-marketing observational study conduct obtain data , safety effectiveness , use lopinavir/ritonavir ( Kaletra ) clinical practice investigate necessity conduct follow-up post-marketing clinical study Japan .</brief_summary>
	<brief_title>Drug Use Investigation Kaletra</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>All patient prescribe Kaletra treatment HIV eligible survey . Contraindications accord Package Insert : Patients history hypersensitivity ingredient Kaletra Patients receive pimozide , cisapride , ergotamine tartrate , dihydroergotamine mesylate , ergometrine maleate , methylergometrine maleate , midazolam , triazolam , vardenafil hydrochloride hydrate , boriconazol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Human Immunodeficiency Virus</keyword>
</DOC>